The effects of high-dose vitamin E supplementation on biomarkers of kidney¬†injury, inflammation, and oxidative¬†stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial
Authors: Esmat Aghadavod
Alireza Soleimani
Parisa Golriz Khatami
Zatollah Asemi
Nasrin Sharifi
Journal: Journal of Clinical Lipidology (2016)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: Diabetic nephropathy; Inflammation; Oxidative stress; Vitamin E; supplementation.
Affiliations: Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran., Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran., Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: .

Abstract:  Background: Limited data are available that evaluated the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy (DN). Objective: This study was conducted to evaluate the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with DN. Methods: This randomized double-blind placebo-controlled clinical trial was carried out among 60 patients with DN. Patients were randomly allocated into two groups to take either 1200 IU/d of vitamin E supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were obtained at the onset of the study and after 12-week intervention to assess biomarkers of kidney injury, inflammation, and oxidative stress. Results: After 12 weeks of intervention, compared with the placebo, vitamin E supplementation resulted in a significant increase in serum vitamin E levels (+42.3 ¬± 13.4 vs -0.8 ¬± 0.8 nmol/mL, P &lt; .001) and a significant decrease in urine protein (-6.8 ¬± 4.3 vs -1.0 ¬± 8.0 mg/dL, P = .001) and protein-to-creatinine ratio (-0.2 ¬± 0.1 vs 0.0 ¬± 0.1, P &lt; .001). In addition, a significant reduction in serum tumor necrosis factor-Œ± (-35.4 ¬± 34.9 vs +5.6 ¬± 6.2 ng/L, P &lt; .001), matrix metalloproteinase-2 (-556.7 ¬± 485.9 vs +60.4 ¬± 53.7 ng/mL, P &lt; .001), matrix metalloproteinase-9 (-1461.5 ¬± 1456.0 vs +225.7 ¬± 488.2 ng/L, P &lt; .001), malondialdehyde (-0.9 ¬± 0.5 vs +0.3 ¬± 0.4 Œºmol/L, P &lt; .001), advanced glycation end products (-1832.2 ¬± 1941.6 vs +177.3 ¬± 324.1 arbitrary unit, P &lt; .001), and insulin concentrations (-0.5 ¬± 2.7 vs +0.7 ¬± 1.0 ŒºIU/mL, P = .03) was seen after the administration of vitamin E supplements compared with the placebo. Supplementation with vitamin E had no significant effects on other biomarkers of kidney injury, fasting plasma glucose, and insulin resistance compared with the placebo. Conclusion: Overall, our study demonstrated that oral high-dose vitamin E supplementation for 12 weeks among DN patients had favorable effects on biomarkers of kidney injury, inflammation, and oxidative stress. 

Retracted: No

PubPeer comments:
 There are many concerns about the integrity of 172 publications by this research group, including this one. Some of the concerns are published 1. Anaesthesia 2020;75:1683u201392, see Supplementary data. This paper is A65 2. Account Res 2020;28:149-61. 3. J Clin Epidemiol 2021;131:22-29. Journals and publishers were notified of these concerns in July 2019. 23 publications have an expression of concern. To our knowledge there has been no public response about any of the concerns. We think these publications are unreliable ,